CN102406840A - Gel binder for treating swelling and pain and its preparation method - Google Patents
Gel binder for treating swelling and pain and its preparation method Download PDFInfo
- Publication number
- CN102406840A CN102406840A CN2011103668800A CN201110366880A CN102406840A CN 102406840 A CN102406840 A CN 102406840A CN 2011103668800 A CN2011103668800 A CN 2011103668800A CN 201110366880 A CN201110366880 A CN 201110366880A CN 102406840 A CN102406840 A CN 102406840A
- Authority
- CN
- China
- Prior art keywords
- ache
- swells
- parts
- ointment
- gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HXKAXGCKNJWPLF-UHFFFAOYSA-N CC(C)(C=C)C=[I](C)(C)N Chemical compound CC(C)(C=C)C=[I](C)(C)N HXKAXGCKNJWPLF-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a compound preparation of an external use pharmaceutical composition for treating swelling and pain, which is a gel binder for treating swelling, and also provides its preparation method. The gel binder is prepared by 20-50% of swelling and pain medicine of the external use pharmaceutical composition for treating swelling and pain as well as proper pharmaceutical excipients. The gel binder for treating swelling is composed of a back lining layer, an ointment-containing body and a cover lining layer. The ointment-containing body, namely the kernel part, is prepared from the swelling and pain medicine, a basic polymer, a cross-linking agent, an organic acid, an excipient, a humectant, an adhesive and the like in certain ratio. The gel binder has the advantages of fast effect, good moisture preservation, high permeability and comfortable use. The product has merits of convenient usage, small irritation on skin and high compliance of patients.
Description
Technical field
The present invention relates to field of pharmaceutical technology, specifically a kind of traumatic injury that can be used for, rheumatic arthritis, scapulohumeral periarthritis, gouty arthritis, gel ointment that swells and ache (external preparation) of cyclomastopathy treatment and preparation method thereof.
Background technology
We disclose the externally-applied medicinal composition (patent No. ZL200510010901.X that a kind of treatment is swollen and ache at Chinese patent 200510010901.X; Patentee: Yunnan Pharmaceutical Institute), be the exterior-applied formulation of processing by following materials of weight proportions: Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) 160-200, Radix Notoginseng 160-200, Radix Aconiti Brachypodi (Radix Aconiti Szechenyiani) 160-200, Delavay ampelopsis root 160-200, Folium Craibiodendri Yunnanensis 160-200, Herba Veratri Taliensis 160-200, Radix Psammosilenes 160-200, Radix Aconiti Kusnezoffii 160-200, colguhoumia root 160-200, Herba Erigerontis 160-200, Radix et Rhizoma Dysosmatis 160-200, Rhizoma Paridis 160-200, Fructus Gardeniae 160-200, Pseudobulbus Bletillae (Rhizoma Bletillae) 160-200, Radix Angelicae Dahuricae 160-200, Radix Glycyrrhizae 50-70, Borneolum Syntheticum 50-70, Mentholum 50-70, Moschus 0.4-1.The said exterior-applied formulation of Chinese patent 200510010901.X is the liniment processed through conventional technology of said raw material and corresponding medicinal adjuvant, aerosol, liniment, rubber-emplastrum, cataplasma, gel etc.Gel, the liniment of said externally-applied medicinal composition, the method for preparing of aerosol are also disclosed in Chinese patent 200510010901.X embodiment simultaneously, but still unexposed gel ointment and preparation method thereof that swells and ache according to the invention.
The externally-applied medicinal composition that a kind of treatment is swollen and ache is the ethnic drug that we develop after scientific validation, develop according to Yi nationality, distributed over Yunnan, Sichuan and Guizhou's secret recipe.Because this Yi nationality, distributed over Yunnan, Sichuan and Guizhou's secret recipe is throughout the year in use among the people, its significant curative effect and safety have obtained a large amount of patients' checking.Safety testings such as the acute toxicity test that we carry out, long term toxicity test, sensitivity test and relevant pharmacodynamics test, clinical trial have been verified scientifically that further it is evident in efficacy and have been had the characteristics of safety.The significant curative effect of the intimate mystery that it reflects in use among the people, clinical trial has obtained affirming and supporting of Yunnan various circles of society.
The present invention updates on the prior art basis and perfect; Our preferred 65～70% ethanol are made the extraction solvent of this externally-applied medicinal composition; After carrying out the percolation effective component extracting,, obtain the medicine that swells and ache of therapeutic dose through screening, the optimization of therapeutic dose; Through a large amount of preparation process research and perfect, successfully developed the gel ointment that swells and ache again.Therefore, the present invention continues to disclose gel ointment of this externally-applied medicinal composition and preparation method thereof on Chinese patent 200510010901.X basis.
Gel ointment system is with medicine dissolution or be mixed in natural and the synthesizing water-solubility macromolecular material substrate; And the stand is applied on the back lining materials, supplies to stick the external preparation in skin, plays general action or local action through Transdermal absorption; Also belong to Percutaneously administrable prepn, its original shape is " poultice ".Because developing rapidly of fields such as modern fine chemistry industry and polymer material science provides the adjuvant of more superior performances for pharmaceutics.Therefore, gel ointment was at first succeeded in developing by Japan in the seventies in last century.In developed country such as American-European-Japanese a large amount of gel ointments listings are arranged by now, receive doctor and patient's favorable comment deeply.China began this dosage form is studied in the eighties in last century, but its development is slower, has only the product of minute quantity to appear on the market till now.
Gel ointment is a kind of high in technological content, the applied range in the world today, novel external plaster agent easy to use, and at the seventies initial stage, states such as Japan, Europe have begun to develop the medical gel unguentum; Continuous development along with medical industry; This novel form develops in China in recent years to some extent, according to World Health Organization's prediction, in afterwards 20～30 years; To there be the medicine more than 30% will make percutaneous drug administration preparation into, will starts the new upsurge of an inner disease outer treat.Compare with traditional external plaster, gel ointment has the following advantages: biocompatibility, affinity, breathability, absorption of perspiration to skin are good, and are not easy allergy; Owing to adopt the water-soluble macromolecule bio-matrix, use back noresidue, not pollution clothes; Because performance of keeping humidity is good, can make the skin keratin cell hydration very soon, helps the Transdermal absorption of medicine, has rapid-action advantage,, use comfortable because permeability is good; To skin nonirritant and sensitization; Can take off subsides repeatedly, not affect the treatment.Gel ointment is as a kind of novel external preparation because use flexibly, convenient, act on characteristics fast, on the external analgesic, praised highly and liked.
Summary of the invention
The object of the invention aims to provide a kind of safe, effective, side effect is little, compliance is good gel ointment and preparation method thereof that swells and ache.
The present invention's gel ointment that swells and ache is to traumatic injury, rheumatic arthritis, scapulohumeral periarthritis, gouty arthritis, a kind of external preparation product of treatment such as cyclomastopathy exploitation.The present invention's externally-applied medicinal composition that gel ointment swells and ache with treatment that swells and ache is a raw material; Through effective component extracting; Process drug gel or solid dispersion (being the medicine that swells and ache of the present invention), the polyacrylic acid (NP700), dihydroxyaluminum aminoacetate, glycerol, tartaric acid, the polyvidone adjuvants such as (K90) that be aided with carbomer (940p) again, partly are neutralized are formulated.
Swell and ache gel ointment system of the present invention is the novel external-use gel unguentum of a kind of pure Chinese medicine of foundational development with " externally-applied medicinal composition that treatment is swollen and ache ".The present invention is on the basis of " externally-applied medicinal composition that treatment is swollen and ache ", and preferred 65～70% ethanol are made the extraction solvent of this externally-applied medicinal composition, carries out obtaining the medicine that swells and ache of the present invention after the technological operation such as percolation extraction; Medicine percolate of the present invention is 65～70% alcoholic acid extracting solution, directly uses because the higher cohesiveness and the adhesion that can change gel cream of concentration of alcohol makes gel ointment hold viscous force and reduce, and is prone to come off, and can't process gel ointment.Concentrate or drying is removed ethanol and can be made drug precipitation or separate out through routine heating, cause the curative effect of medicine to reduce, long through lyophilization or cryogenic vacuum spray drying time, the production cost height, and be difficult to find suitable dissolution with solvents medicine.After the present invention processes gel or solid dispersion with medicine percolate and gel-type vehicle or solid dispersion host material; Because macromolecular material is to the effects such as solubilising of medicine; Can heated volatile remove part ethanol (can not cause the ingredient deposition or separate out); Both can reduce the effect of ethanol to gel cream; Avoid weakening of adhesion, the medicine that swells and ache is distributed with molecularity in gel cream, the chemical stability of medicine in gel ointment and the curative effect of product help swelling and ache.
Gel-type vehicle of the present invention can be one or more in carbomer, polyvinyl alcohol, polyacrylic acid and the sodium salt thereof etc.
Solid dispersion substrate of the present invention can be one or more in polyvinylpyrrolidone, Polyethylene Glycol, methylcellulose and carboxymethyl cellulose and sodium salt, the hydroxypropyl emthylcellulose etc.
The present invention's medicine that swells and ache has significant antiinflammatory, analgesia, microcirculation improvement, inhibition gouty arthritis and suppresses the effect of cyclomastopathy etc.
The gel ointment that swells and ache of the present invention is " described gel ointment of version in 2010 of Chinese pharmacopoeia of being processed by the pharmaceutic adjuvant that allows on the swell and ache medicine and the pharmaceutics of therapeutic dose to add.
The present invention's gel ointment that swells and ache is made up of backing layer, ointment-containing body and lid lining (protecting film) three parts.Ointment-containing body contains the medicine that swells and ache of therapeutic dose; With one or more pharmaceutic adjuvants, comprise in basic polymer, cross-linking agent, organic acid, excipient, wetting agent, binding agent, purified water, solvent, antiseptic and the materials such as antioxidant, surfactant one or more; The employed back lining materials of backing layer can be a kind of in cotton, spun rayon cloth, non-woven fabrics, the flannel; Lid lining protecting film employed lid lining material can be a kind of in separate paper, polypropylene film, polyethylene film, cellophane, polyester, the aluminium foil-polyethylene composite film.The swell and ache specification of gel ointment of the present invention is the specification of conventional emplastrum; According to different specifications, every subsides amount that contains the medicine that swells and ache in the gel ointment that swells and ache is 1.0 grams～8.0 grams, and every subsides preferred amounts that contains the medicine that swells and ache in the gel ointment that swells and ache is 2.0 grams～4.0 grams.
Of the present inventionly swell and ache gel ointment by weight percentage, be grouped into by following one-tenth:
Wherein, the medicine that swells and ache is to be made by following method: take by weighing 6 parts of raw material Borneolum Syntheticums by weight ratio, 6 parts of Mentholums, Moschus add ethanol for 0.08 part makes it dissolving, 18 parts of all the other Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae)s in right amount; 18 parts of Delavay ampelopsis root, 18 parts of Folium Craibiodendri Yunnanensiss, 18 parts of Herba Veratri Taliensis, 18 parts of Radix Psammosileness, 18 parts of Radix Aconiti Brachypodi (Radix Aconiti Szechenyiani)s; 18 parts of Radix Aconiti Kusnezoffii, 18 parts of colguhoumia roots, 18 parts of Herba Erigerontiss, 18 parts of Radix Notoginseng, 18 parts of Radix et Rhizoma Dysosmatiss; 18 parts of Rhizoma Paridis, 18 parts of Fructus Gardeniae, 18 parts of Pseudobulbus Bletillae (Rhizoma Bletillae), 18 parts of the Radixs Angelicae Dahuricae, Radix Glycyrrhizae is ground into coarse powder for 6 parts; Mixing according to the percolation (appendix I 0 of Chinese Pharmacopoeia version in 2010) under fluid extract and the extractum item, is made solvent with 65～70% ethanol, carries out percolation; Collect 1000 parts of percolates, cold preservation 48 hours is filtered, and is subsequent use.Get gel-type vehicle or solid dispersion substrate is an amount of, add above-mentioned subsequent use percolate, abundant stirring and dissolving, heated volatile is removed part ethanol in water-bath, when being chilled to 40 ℃, adds alcoholic solution such as Borneolum Syntheticum, stirs, and promptly gets 750 parts of the medicines of swelling and ache.
Medicine of the present invention has Repercusion analgesia, blood circulation promoting and blood stasis dispelling, and relaxing muscles and tendons and removing obstructionfrom meridians, the effect of eliminating mass and relieving fullness eliminating stagnation is used for treatment type of swelling and ache disease, so it is named as the medicine that swells and ache; Dosage form is a gel ointment, so it is named as the gel ointment that swells and ache.
The method for preparing of the gel ointment that swells and ache of the present invention is:
(1) wetting agent is fully mixed with basic polymeric matrix, cross-linking agent, excipient etc., add the medicine that swells and ache, under vacuum condition, fully mix 1.;
(2) dissolve 2. with suitable quantity of water binding agent, organic acid etc.;
(3) in will 2. joining 1., under vacuum condition, fully mix, obtain ointment-containing body, the ointment-containing body coating is got final product through cross-linking reaction.
Its preparation process is following:
Its preparation principle is following:
Basic polymer fully mixes with cross-linking agent (microsolubility polyvalent metal compounds such as aluminium compound) and medicine etc.; The adding organic acid slowly dissolves cross-linking agent and discharges metal ion (like aluminium ion), and basic polymer and metal ion (like aluminium ion) are cross-linked to form gel.Through control gel formation speed, thereby make crosslinked and coating process etc. easier.
Basic polymer of the present invention can be the polyacrylic acid that degree of neutralization does not wait, carbomer, carboxymethyl cellulose and sodium salt thereof, one or more in the polyvinyl alcohol etc.The polyacrylic acid that degree of neutralization does not wait comprises: sodium polyacrylate, F-500, NP-600, NP-700, NP-800 etc.Carbomer comprises: Carbopol 934, and Carbopol 940, Carbopol 97l etc.
Cross-linking agent of the present invention can be an aluminium hydroxide, dihydroxyaluminum aminoacetate, aluminum chloride, one or more in the disodiumedetate (EDTA) etc.
Organic acid of the present invention can be a lactic acid, tartaric acid, one or more in the citric acid etc.
Wetting agent of the present invention can be a glycerol, propylene glycol, Polyethylene Glycol, one or more in the sorbitol etc.
Sticker of the present invention can be a sodium alginate, methylcellulose, one or more in the polyacrylic acid that sodium carboxymethyl cellulose, polyvinyl alcohol, polyvinylpyrrolidone, carbomer, degree of neutralization do not wait etc.Polyvinylpyrrolidone comprises: PVPK-30, PVPK-90 etc.Sticker of the present invention can be used for preventing that drug crystallization from separating out and as the medicine stabilizing agent.
Excipient of the present invention can be carboxymethyl cellulose (CMC), carbopol (CVP), one or more in the crospolyvinylpyrrolidone (PVPP) etc.Excipient of the present invention can be retained in solvent and/or wetting agent in the gel, is easy to gel coated and the advantage that prevents the contraction of gel structure in addition.
The present invention becomes also can add in the materials such as antiseptic and antioxidant, surfactant, filler, metal-chelator one or more in being grouped into; The common cooperation reaches solubilize drugs and promotes effects such as drug osmotic and the generation of minimizing bubble.
Gel ointment of the present invention compared with prior art possesses following characteristics:
1. biocompatibility, affinity, breathability, the absorption of perspiration to skin is good, and is not easy allergy;
2. performance of keeping humidity is good, can make the skin keratin cell hydration very soon, helps the Transdermal absorption of medicine, has rapid-action advantage,
3. permeability is good, uses comfortable;
4. to skin nonirritant and sensitization, be not easy allergy; And this gel ointment is subsides every day one, and therefore every patch amount is less, and the skin malaise symptoms takes place less.
Product of the present invention is through pharmacodynamics test, and its exercising result at aspects such as antiinflammatory, analgesias is following:
One, immune inflammation
Effect to rat assist agent arthritis
Get 80 of 150～200g male rats; Be divided into blank control group, model control group, indometacin, gel ointment matrix group, the gel ointment that swells and ache (low, high, in) group at random; Every group 10; Except that indometacin group every day according to dosage the gastric infusion 1 time, all the other each treated animals equal every days is according to dosage in the following coating in right back ankle joint (pure water), continuous 6 days.Before the last coating, sufficient normal volume about measuring earlier, behind the coating 30 minutes, in every right back sufficient plantar subcutaneous injection Freund ' s Freund's complete adjuvant 0.1ml of rat, except the blank control group.Cause after the inflammation more continuously coating 26 days.And sufficient volume about the interval certain hour was measured after 2h, 24h, 3d reached behind the Yu Zhiyan, the preceding foot swelling of rat and tail, ear's erythema situation and body weight change after attention observation simultaneously causes scorching 8 days, and press document
[1]Standard keeps the score for every Mus delayed hypersensitivity, until causing scorching back 28 days.The 28th day, measure the inflammation foot swelling rate all around that causes, relatively the significance of each item index group difference.The result is as follows:
The result shows: the high, medium and low dose groups of the gel ointment that swells and ache all can suppress foot swelling due to the adjuvant arthritis rats, and can reduce the arthritis index of adjuvant arthritis rats.The results suggest gel ointment that swells and ache has inhibitory action to the adjuvanticity rat arthritis.
Influence (the mL of table 1 pair adjuvant arthritis rats paw swelling; N=10;
)
Annotate: compare with blank control group: * P＜0.05, * * P＜0.01, * * * P＜0.001; Compare with model group:
△P＜005,
△ △P＜001,
△ △ △P＜0001; Compare with blank matrix group:
▲P＜0.05
Influence (the n=10 of table 2 pair adjuvant arthritis rats arthritis index;
)
Annotate: compare with blank control group: * P＜0.05, * * P＜0.01, * * * P＜0.001; Compare with model group:
△P＜005,
△ △P＜001; Compare with blank matrix group:
▲P＜0.05
Two, to the effect of gouty arthritis
1. uric acid sodium is induced the influence of rat gouty arthritis
80 male rats are divided into 8 groups at random, 10 every group.Each the treated animal every day of administration according to dosage, for three days on end; After the last administration 30 minutes, except that blank group rat the foot pad injecting normal saline 0.05ml of portion of the right side, all the other respectively organize rat on the right side foot pad portion injection uric acid sodium normal saline suspension 0.05ml, induce the generation of gouty arthritis.Respectively with vernier caliper measurement cause scorching before and cause the thickness of the right sufficient pad of scorching back 1h, 2h, 4h, 6h and 8h rat portion so that the difference before and after scorching is as the swelling degree of gouty arthritis, take the mean and model control group relatively, carry out statistical test.
Table 3 influence (
n=10) of gel ointment of swelling and ache to the rat gouty arthritis
Annotate: compare with the blank group: * P＜0.05, * * P＜0.01, * * * P＜0.001; Compare with the solvent group:
△P＜0.05,
△ △P＜0.01,
△ △ △P＜0.001
Result of the test shows (seeing table 3): after the modeling of uric acid sodium, model group and blank group relatively have significant difference (P＜0.01), prove the success of the inductive rat gouty arthritis of uric acid sodium model.The high, medium and low dosage of the gel ointment that swells and ache all has significant inhibitory effect at different time to the inductive rat paw edema of urate, and wherein low dosage 1h after modeling has demonstrated significant inhibitory effect.Point out the gel ointment that swells and ache that the rat gouty arthritis is had significant antagonism.
2. to the influence of uric acid sodium inducing mouse gouty arthritis
60 male mices; Divide into groups and medication sees the following form, after the last administration 30 minutes, except that blank group mice the foot pad injecting normal saline 0.05ml of portion of the right side; All the other respectively organize mice at the injection uric acid sodium normal saline suspension 0.05ml of right side foot pad portion, induce the generation of gouty arthritis.Respectively with vernier caliper measurement cause scorching before and cause the diameter at 0.5cm place under scorching back 1h, 2h, 4h and the 6h mice ankle joint so that the difference before and after scorching is as the swelling degree of gouty arthritis, takes the mean and model control group compares, and carries out statistical test.
Table 4 influence (
n=10) of gel ointment of swelling and ache to the mice gouty arthritis
Annotate: compare with the blank group: * P＜0.05, * * P＜0.01, compare with the solvent group:
△P＜0.05,
△ △P＜0.01,
△ △ △P＜0.001
Result of the test shows (seeing table 4): the basic, normal, high dosage of the gel ointment that swells and ache all has remarkable inhibitory action at different time to the inductive mice foot swelling of urate, and especially low, middle dosage 1h, 2h, 4h after modeling have the inhibitory action of highly significant.Point out the gel ointment that swells and ache that the mice gouty arthritis is had significant antagonism.
Three, antiinflammatory action
1. to the influence of rat carrageenan foot swelling
80 male rats are divided into 8 groups at random, 10 every group.Each the treated animal every day of administration according to dosage, for three days on end; After the last administration 30 minutes, the carrageenin normal saline suspension 0.1ml of right sufficient pad portion subcutaneous injection 1%.With vernier caliper measurement measure respectively cause scorching before and cause the thickness of the right sufficient pad of scorching back 0.5h, 1h, 2h, 3h, 4h portion so that before and after scorching the difference of thickness as the swelling degree, take the mean and model control group relatively, carry out statistical test.The result sees table 5
Table 5 swells and ache gel ointment to the bullate influence (
n=10) of rat carrageenan foot
Compare with the blank group:
△P＜0.05,
△ △P＜0.01.Compare with model group:
*P＜0.05,
*P＜0.01.Compare with the solvent group:
▲P＜0.05,
▲ ▲P＜0.01
Result of the test shows: after the carrageenin modeling, model group and blank group relatively have significant difference (P＜0.01), prove the model success.It is swollen that 3 dosage of gel ointment that swell and ache all can significantly suppress rat carrageenan foot, particularly in, low dosage causing 2,3 hours the inhibitory action highly significant in scorching back.Prompting is swollen and ache gel ointment to the sufficient swollen significant antiinflammatory action that has of rat carrageenan.
2. Oleum Tiglii is caused the influence of mice auricle swelling
Get 72 of 18～22g mices, male and female half and half are divided into blank control group, indometacin, gel ointment matrix group, the gel ointment that swells and ache (basic, normal, high) group, 12 every group at random.Except that indometacin group every day according to dosage the gastric infusion 1 time, each treated animal every day is auris dextra coating (substrate contrast) according to dosage, continuous 5 days; After the last administration 45 minutes, every Mus auris dextra two sides is evenly smeared 0.05ml Oleum Tiglii and is caused inflammation, causes scorching back 30 minutes repaste medicines 1 time; Put to death animal on time after causing scorching back 60 minutes, with the card punch of diameter 6mm with ears with the cutting-out of position homalographic, weigh; As the swelling degree, calculate inhibitory rate of intumesce with the difference of two auricle weight.The result is as follows:
Table 6 gel ointment that swells and ache causes the influence
of mice auricle swelling to Oleum Tiglii
Annotate: compare with blank control group:
*P＜0.05,
*P＜0.01; Compare with blank matrix group:
△P＜0.05,
△ △P＜0.01,
△ △ △P＜0.001
The result shows: the basic, normal, high dose groups of the gel ointment that swells and ache has inhibitory action to Oleum Tiglii induced mice auricle edema; Compare with blank control group (P＜0.05 that has significant difference; P＜0.05, P＜0.01), suppression ratio is respectively: 27.69%, 32.79%, 37.02%.Compare with blank matrix group, the basic, normal, high dose groups of the gel ointment that swells and ache has inhibitory action (P＜0.05, P＜0.05, P＜0.01) to Oleum Tiglii induced mice auricle edema.The results suggest gel ointment that swells and ache has inhibitory action to the acute inflammation of Oleum Tiglii induced mice auricle edema.
3. to the influence of mice granuloma induced by implantation of cotton pellets
Get 72 of 23-25g male mices, be divided into 6 groups at random, 12 every group, divide into groups and administration, except that indometacin group every day according to dosage the gastric infusion 1 time, each organizes mouse web portion QUMAO coating (substrate contrast).Each Mus under aseptic condition in the left and right sides the subcutaneous heavy sterilization cotton balls of 6mg of respectively implanting of hind leg footpath portion.From performing the operation the same day each the treated animal every day of left and right sides hind leg footpath according to dosage portion coating 1 time, successive administration 13 days.Mice is put to death in the back of weighing in the 14th day, opens former otch, and cotton balls is taken out together with connective tissue on every side, rejects fatty tissue, in 70 ℃ of drying in oven, weighs, and calculates and respectively organizes granuloma weight and granulation coefficient.The result sees table 7
Table 7 influence
of gel ointment of swelling and ache to the mice granuloma induced by implantation of cotton pellets
Annotate: compare with the blank group: * P＜0.05, * * P＜0.01, compare with blank matrix group:
△P＜0.05,
△ △P＜0.01,
△ △ △P＜0.001
The result shows: compare with the blank group, the basic, normal, high dose groups of the gel ointment that swells and ache has obvious influence (P＜0.05, P＜0.05, P＜0.01) to the minimizing of mice granuloma induced by implantation of cotton pellets; Compare with blank matrix group; The basic, normal, high dose groups of the gel ointment that swells and ache has obvious influence (P＜0.05 to the minimizing of mice granuloma induced by implantation of cotton pellets; P＜0.01, P＜0.001) point out the gel ointment that swells and ache that the chronic inflammatory disease due to the mice granuloma induced by implantation of cotton pellets is had inhibitory action.
Four, analgesic activity
1. the Dichlorodiphenyl Acetate induced mice is turned round the influence of body property pain
Get 72 of 18～22g mices, male and female half and half are divided into blank control group, aspirin, gel ointment matrix group, the gel ointment that swells and ache (high, medium and low) group, 12 every group at random.Except that aspirin group every day according to dosage the gastric infusion 1 time; Each organizes mouse web portion QUMAO coating (substrate contrast); Continuous 4 days, after 30 minutes, the glacial acetic acid 0.2ml/ of every Mus lumbar injection 0.6% only in the last administration; In the observed and recorded 15 minutes mice pain turn round the body number of times, and calculate the analgesia suppression ratio.The result is as follows:
The table 8 gel ointment Dichlorodiphenyl Acetate that swells and ache causes the influence
of mouse writhing reaction
Annotate: compare with blank control group: * P＜0.05, * * P＜0.01; Compare with blank matrix group:
△P＜0.05,
△ △P＜0.01 result shows: the basic, normal, high dose groups Dichlorodiphenyl Acetate of the gel ointment that swells and ache causes the mice painful and turns round body inhibitory action is arranged; Compare with blank control group (P＜0.05 that has significant difference; P＜0.01, P＜0.05), suppression ratio is respectively: 49.17%, 54.70%, 48.45%; Compare with blank matrix group, the basic, normal, high dose groups Dichlorodiphenyl Acetate of the gel ointment that swells and ache causes the mice painful and turns round body inhibitory action (P＜0.05, P＜0.01, P＜0.05) is arranged.The results suggest body of turning round that the gel ointment Dichlorodiphenyl Acetate causes the mice painful that swells and ache has inhibitory action.
2. the mice hot plate is caused the influence of pain reaction
Select the 18-22 female mice, on the hot plate dolorimeter, measure pain threshold 3 times (is observation index the licking metapedes reaction to occur) before the experiment, select 70 of 3 the qualified mices of pain threshold in 5s-30s, be divided into 7 groups at random, 10 every group.Each treated animal every day is according to dosage at the foot coating, for three days on end; 15min, 30min, 60min lick sufficient incubation period with stopwatch record mice respectively and make pain threshold after the last administration, take the mean and matched group relatively, carry out statistical test.
Table 9 gel ointment that swells and ache causes the influence (
n=10) of pain reaction to the mice hot plate
Compare with model group:
*P＜0.05,
*P＜0.01.Compare with matrix group:
▲P＜0.05,
▲ ▲P＜0.01
Result of the test (seeing table 9) shows: three dosage of gel ointment that swell and ache all can significant prolongation mice hot plate cause the incubation period of pain reaction, in its analgesic activity, low dosage still has the characteristics of imitating long action time.
Five, the pain relieving capsule influences microcirculation of mouse auricle
Get 50 of 17.5-20g mices, male and female half and half are divided into 10 every group of blank control group, blank matrix group, the different third kidney group, the gel ointment that swells and ache (basic, normal, high dose groups) at random.Laboratory temperature remains on 25 ± 1 ℃.Each treated animal according to dosage is administered once every day, continuous three days.Behind the last administration 30min; With pentobarbital sodium 60mg/kg body weight intraperitoneal injection of anesthesia animal, fixedly auricle places under the microcirculation microscope of amplifying 50 times; With suitable blood vessel (boundary clear; The spy is tremulous pulse, vein blood vessel very obviously) be the object of observation, cause experimental microcirculation disturbance by the dosage of 0.1mg/kg to mouse peritoneal injection isoprenaline, gather respectively before the moulding (for guaranteeing the picture quality of collection; According to preliminary experiment; Image is gathered modeling immediately after the collection in anesthesia back 5min before the modeling), after the moulding 5,10 and the image during 15min, observe following four indexs: 1. (fluidised form is divided 5 grades: stagnation is 0 minute to blood fluidised form (carrying out simultaneously with IMAQ); Grain stream is 1 minute, and the grain linear flow is 2 minutes, and line grain stream is 3 minutes, and linear flow is 4 minutes); 2. arteriole caliber (A
3); 3. venule caliber (V
3); 4. capillary network is counted.Observe and write down the situation of change of administration front and back each item index, to judge that medicine is to microcirculatory improvement situation.(objectivity and minimizing personal error for guaranteeing experimental result in the test; Animal Anesthesia, auricle are fixed, IMAQ, and the scoring of blood fluidised form, blood vessels caliber measurement etc. influence the step of experimental result easily; By passing through the preliminary experiment training; The personnel that can skillfully operate) result sees table 10,11,12
Table 10 swell and ache gel ointment to the influence of Mice Auricle arteriole caliber (
um, n=12)
Compare * P＜0.05, * * P＜0.01, * * * P＜0.001 with blank control group; Compare with matrix group:
▲P＜0.05,
▲ ▲P＜0.01,
▲ ▲ ▲P＜0.01
Table 11 swell and ache gel ointment to the influence of Mice Auricle venule caliber (
um, n=12)
Compare * P＜0.05, * * P＜0.01, * * * P＜0.001 with blank control group; Compare with matrix group:
▲P＜0.05,
▲ ▲P＜0.01,
▲ ▲ ▲P＜0.01
Table 12 swell and ache gel ointment to the influence of the open number of Mice Auricle blood capillary (
um, n=12)
Compare * P＜0.05, * * P＜0.01, * * * P＜0.001 with blank control group; Compare with matrix group:
▲P＜0.05,
▲ ▲P＜0.01,
▲ ▲ ▲P＜0.01
Table 13 swell and ache gel ointment to the influence of Mice Auricle hemorheology (
um, n=12)
Compare * P＜0.05, * * P＜0.01, * * * P＜0.001 with blank control group; Compare with matrix group:
▲P＜0.05,
▲ ▲P＜0.01,
▲ ▲ ▲P＜0.01
Experimental result shows: the gel ointment that swells and ache can obviously improve the hemorheology index of rat acute blood stasis model due to the adrenal gland; Obviously arteriole, venule caliber and the blood capillary of experimental microcirculation disturbance mice opened number due to the increase epinephrine.Six, to the influence of rat mammary gland cyclomastopathy pathological model
It is some to get rat, every day axillary fossa subcutaneous injection estradiol benzoate 0.5mg/kg, continuously 25d changes afterwards and annotates Progesterone 1mg/kg, continuously 5d.Reject breast increase the not obvious (rat of substrate＜3mm) next day after the drug withdrawal; Randomly drawing 10 rats then puts to death; Select a breast that obviously increases to make histopathological examination for every, increase expansions, lumen of gland hydrops, glandular cell with the mammary gland acinus and increase the positive glandular cell of hypertrophy, glandular tissue estrogen receptor positive glandular cell and progesterone receptor all to account for the whole glandular cell 20% above persons of microscopic field be successful hyperplasia of mammary lobule change.It is successful for this batch rat mammary gland cyclomastopathy model that the breast tissue pathological examination of 10 rats has 8 above rat breasts to meet this pathological change.It begins to be used for subsequent experimental and is not later than 3d behind the Progesterone of stopping using.Normal control group and model group are fed with pure water.Medicine feed 50 days is behind last medicine feed 5h, with the variation of second pair of breast diameter of vernier caliper measurement rat; Carry out statistical test.
The influence of table 14 pair rat mammary gland cyclomastopathy pathological model
Compare * P＜0.05, * * P＜0.01, * * * P＜0.001 with blank control group; Compare with matrix group:
▲P＜0.05,
▲ ▲P＜0.01,
▲ ▲ ▲P＜0.01, compare with model group:
△P＜0.05,
△ △P＜0.01,
△ △ △P＜0.01
The influence of table 15 pair rat uterus weight
Compare * P＜0.05, * * P＜0.01, * * * P＜0.001 with blank control group; Compare with model group:
▲P＜0.05,
▲ ▲P＜0.01,
▲ ▲ ▲P＜0.01,
The estrogen of rat rising after modeling in the experiment; Progestogen reduce; And the diameter of its breast is also from little change big (P＜0.01), and after the treatment of utilization mammary gland health, the breast diameter of rat is reduced to normally (with the normal group comparison from expansion; P＞0.05), can obviously alleviate the cyclomastopathy lesion degree of rat due to the diethylstilbestrol; Increase to the modeling uterus weight also has obvious inhibitory action.
Seven, to 2, the influence of 4-dinitrofluorobenzene inducing mouse delayed hypersensitivity
Select 108 of 18～22g mices for use, male and female half and half are divided into 9 groups at random by sex and body weight, and each 6 of every group of male and female are divided into groups and the administration situation is seen table 7.Each treated animal every day is gastric infusion 1 time according to dosage; Continuous 9 days; Matched group is irritated clothes and is waited the capacity pure water, and positive control prednisolone acetate group was irritated stomach with each administration group in the 1st, 3,5,7,9 days in administration and given prednisolone acetate 10mg/kg, and each group is irritated the stomach volume and is the 20ml/kg body weight.Except that the blank group, all the other each treated animals 1h after first administration evenly smears 50ul/ sensitization of 1%DNFB mixed liquor in skin of abdomen, and respectively strengthens 1 time in the 2nd, 3 day.Administration the 9th day; Evenly smearing the 1%DNFB mixed liquor in each Mus auris dextra two sides with the volume of every ear 10ul attacks; Left side ear is coated with equivalent acetone: oily mixed liquor is as contrast, excites back 16h to take off cervical vertebra and puts to death animal, with the card punch of diameter 6mm ears downcut with the position homalographic; Get auricle and weigh, with about the difference of two auricle weight be that the swelling degree is as the delayed hypersensitivity value.
Table 16 swells and ache gel ointment to 2, the influence of 4-dinitrofluorobenzene inducing mouse delayed hypersensitivity
Compare with matched group: * p＜0.05, compare with model group: △ p＜0.05
Experimental result shows that the gel ointment administration 9 days of swelling and ache can increase the delayed hypersensitivity that is caused the immunologic hypofunction mice by prednisolone acetate in various degree.Has immunoregulation effect.
Product of the present invention is through safety testing, and its result is following:
Acute toxicity testing: exempt from intact skin and the administration of damaged skin succession through family, do not see that high and low dose treated animal breakage property skin wound produces slight erythema, but do not find that epiderm skin and corium have any pathological changes; The overt toxicity reaction appears in outward appearance, behavioral activity, hair luster, eye and the mucosa, breathing and the central nervous system that do not see animal.
Long term toxicity test: exempt from intact skin to family and slight skin irritation reaction just appears in the damaged skin successive administration after 16 days with 25 times of clinical consumptions and 50 multiple doses.
Skin allergy experiment: guinea pig skin is not had anaphylaxis.
Gel ointment of the present invention compared with prior art possesses following characteristics:
1. biocompatibility, affinity, breathability, the absorption of perspiration to skin is good, and refrigerant sense is arranged, and to skin nonirritant and sensitization, is not easy allergy, uses comfortablely, uses the back noresidue, and pollution clothes can not taken off subsides repeatedly, does not affect the treatment.
2. performance of keeping humidity is good, can make the skin keratin cell hydration very soon, helps the Transdermal absorption of medicine, in addition, owing to Borneolum Syntheticum, Mentholum, Moschus etc. can make cutaneous vasodilation, promotes other medicines to absorb fast.Therefore, has rapid-action advantage.
3. can directly act on the sufferer place, avoid the degraded and the liver first-pass effect of intestines and stomach, drug effect is rapid and reduced untoward reaction, has avoided the infringement of medicine to liver, renal function, and security performance is high.
4. paste every day one, can keep long-time release, reduce the medication number of times, easy to use, patient's compliance is high, is fit to long-term prescription.
Product trial volunteer trial effect of the present invention
50 trial volunteers molding on probation gel ointment that swells and ache, to film residual, skin tracing ability, comfort, skin malaise symptoms, take off and pull pain etc. and estimate, the result sees the following form:
The result shows: product of the present invention to film residual, skin tracing ability, comfort, skin malaise symptoms, take off that to pull pain all better, can take off repeatedly and pull and apply ointment or plaster.It is good to biocompatibility, affinity, breathability, the absorption of perspiration of skin that results suggest the present invention produces product, and be not easy allergy.
The specific embodiment
Following embodiment further specifies what invent, but it is not meaned to any restriction to invention.
Embodiment 1
Backing layer: non-woven fabrics
Lid lining: embossing polyester film
Ointment-containing body layer component constitutes following by weight percentage:
Method for preparing:
(1) takes by weighing glycerol (wetting agent) by recipe quantity, in glycerol, add polyacrylic acid NP-700 (basic polymer), the dihydroxyaluminum aminoacetate (cross-linking agent) of recipe quantity successively, fully mix, add the medicine that swells and ache, under vacuum condition, fully mix 1.;
(2) take by weighing purified water by recipe quantity, tartaric acid (organic acid), the polyvinylpyrrolidone-K90 (binding agent) of recipe quantity is dissolved in water and gets 2.;
(3) in will 2. joining 1., under vacuum condition, fully stir, obtain ointment-containing body through cross-linking reaction; With ointment-containing body coating (control ointment-containing body layer thickness is about 1.0mm), be cut into conventional emplastrum specification (as: the long 9cm of every subsides * wide 6cm, the amount that every subsides contain the medicine that swells and ache is 2.0 to restrain; Or being cut into the long 10cm of every subsides * wide 6.8cm, the amount that every subsides contain the medicine that swells and ache is 2.5 grams, or is cut into the long 11cm of every subsides * wide 7.5cm; The amount that every subsides contain the medicine that swells and ache is 3.0 grams); Dry, packing, the gel ointment finished product promptly swells and ache.
Embodiment 2
Backing layer: non-woven fabrics
Lid lining: aluminium foil-polyethylene composite film
Ointment-containing body layer component constitutes following by weight:
Method for preparing:
(1) takes by weighing glycerol (wetting agent) by recipe quantity, in glycerol, add polyacrylic acid NP-600 (basic polymer), the aluminium hydroxide (cross-linking agent) of recipe quantity successively, fully mix, add the medicine that swells and ache, under vacuum condition, fully mix 1.;
(2) take by weighing purified water by recipe quantity, lactic acid (organic acid), the sodium carboxymethyl cellulose (binding agent) of recipe quantity is dissolved in water and gets 2.;
(3) in will 2. joining 1., under vacuum condition, fully stir, obtain ointment-containing body through cross-linking reaction; With ointment-containing body coating (control ointment-containing body layer thickness is about 1.0mm), be cut into conventional emplastrum specification (as: the long 9cm of every subsides * wide 6cm, the amount that every subsides contain the medicine that swells and ache is 1.0 to restrain; Or being cut into the long 10cm of every subsides * wide 6.8cm, the amount that every subsides contain the medicine that swells and ache is 1.3 grams, or is cut into the long 11cm of every subsides * wide 7.5cm; The amount that every subsides contain the medicine that swells and ache is 1.5 grams); Dry, packing, the gel ointment finished product promptly swells and ache.
Embodiment 3
Backing layer: non-woven fabrics
Lid lining: embossing polyethylene film
Method for preparing:
(1) takes by weighing glycerol (wetting agent) by recipe quantity, in glycerol, add polyacrylic acid F-500 (basic polymer), the dihydroxyaluminum aminoacetate (cross-linking agent) of recipe quantity successively, fully mix, add the medicine that swells and ache, under vacuum condition, fully mix 1.;
(2) take by weighing purified water by recipe quantity, the tartaric acid (organic acid) of recipe quantity is dissolved in water gets 2.;
(3) in will 2. joining 1., under vacuum condition, fully stir, obtain ointment-containing body through cross-linking reaction; With ointment-containing body coating (control ointment-containing body layer thickness is about 1.0mm), be cut into conventional emplastrum specification (as: the long 9cm of every subsides * wide 6cm, the amount that every subsides contain the medicine that swells and ache is 5.2 to restrain; Or being cut into the long 10cm of every subsides * wide 6.8cm, the amount that every subsides contain the medicine that swells and ache is 6.6 grams, or is cut into the long 11cm of every subsides * wide 7.5cm; The amount that every subsides contain the medicine that swells and ache is 8.0 grams); Dry, packing, the gel ointment finished product promptly swells and ache.
Embodiment 4
Backing layer: non-woven fabrics
Lid lining: separate paper
Ointment-containing body layer component constitutes following by weight:
Method for preparing:
(1) takes by weighing glycerol and propylene glycol (wetting agent) by recipe quantity; The polyacrylic acid NP-800 (basic polymer), crospolyvinylpyrrolidone, the aluminium hydroxide (cross-linking agent) that in glycerol and propylene glycol, add recipe quantity successively; Fully mix; Add the medicine that swells and ache, under vacuum condition, fully mix 1.;
(2) take by weighing purified water by recipe quantity, lactic acid (organic acid), the polyvinylpyrrolidone-K30 (binding agent) of recipe quantity is dissolved in water and gets 2.;
(3) in will 2. joining 1., under vacuum condition, fully stir, obtain ointment-containing body through cross-linking reaction; With ointment-containing body coating (control ointment-containing body layer thickness is about 1.0mm), be cut into conventional emplastrum specification (as: the long 9cm of every subsides * wide 6cm, the amount that every subsides contain the medicine that swells and ache is 1.5 to restrain; Or being cut into the long 10cm of every subsides * wide 6.8cm, the amount that every subsides contain the medicine that swells and ache is 1.8 grams, or is cut into the long 11cm of every subsides * wide 7.5cm; The amount that every subsides contain the medicine that swells and ache is 2.3 grams); Dry, packing, the gel ointment finished product promptly swells and ache.
Embodiment 5
Backing layer: artificial cloth
Lid lining: polypropylene film
Ointment-containing body layer component constitutes following by weight:
Method for preparing:
(1) takes by weighing glycerol (wetting agent) by recipe quantity, in glycerol, add polyacrylic acid NP-700 (basic polymer), the dihydroxyaluminum aminoacetate (cross-linking agent) of recipe quantity successively, fully mix, add the medicine that swells and ache, under vacuum condition, fully mix 1.;
(2) take by weighing purified water by recipe quantity, tartaric acid (organic acid), the polyvinylpyrrolidone-K90 (binding agent) of recipe quantity is dissolved in water and gets 2.;
(3) in will 2. joining 1., under vacuum condition, fully stir, obtain ointment-containing body through cross-linking reaction; With ointment-containing body coating (control ointment-containing body layer thickness is about 1.0mm), be cut into conventional emplastrum specification (as: the long 9cm of every subsides * wide 6cm, the amount that every subsides contain the medicine that swells and ache is 1.8 to restrain; Or being cut into the long 10cm of every subsides * wide 6.8cm, the amount that every subsides contain the medicine that swells and ache is 2.3 grams, or is cut into the long 11cm of every subsides * wide 7.5cm; The amount that every subsides contain the medicine that swells and ache is 2.7 grams); Dry, packing, the gel ointment finished product promptly swells and ache.
Embodiment 6
Backing layer: non-woven fabrics
Lid lining: embossing polypropylene film
Ointment-containing body layer component constitutes following by weight:
Method for preparing:
(1) takes by weighing glycerol (wetting agent) by recipe quantity, in glycerol, add polyacrylic acid NP-700 (basic polymer), the dihydroxyaluminum aminoacetate (cross-linking agent) of recipe quantity successively, fully mix, add the medicine that swells and ache, under vacuum condition, fully mix 1.;
(2) take by weighing purified water by recipe quantity, tartaric acid (organic acid), the polyvinylpyrrolidone-K90 (binding agent) of recipe quantity is dissolved in water and gets 2.;
(3) in will 2. joining 1., under vacuum condition, fully stir, obtain ointment-containing body through cross-linking reaction; With ointment-containing body coating (control ointment-containing body layer thickness is about 1.0mm), be cut into conventional emplastrum specification (as: the long 9cm of every subsides * wide 6cm, the amount that every subsides contain the medicine that swells and ache is 2.6 to restrain; Or being cut into the long 10cm of every subsides * wide 6.8cm, the amount that every subsides contain the medicine that swells and ache is 3.3 grams, or is cut into the long 11cm of every subsides * wide 7.5cm; The amount that every subsides contain the medicine that swells and ache is 4.0 grams); Dry, packing, the gel ointment finished product promptly swells and ache.
Claims (7)
1. the gel ointment and preparation method thereof that swells and ache is characterized in that the ointment-containing body in the gel ointment is processed with suitable pharmaceutic adjuvant by the medicine 20%～50% that swells and ache.
2. the gel ointment that swells and ache according to claim 1 is characterized in that the amount that ointment-containing body in every subsides gel ointment contains the medicine that swells and ache is 1.0 grams～8.0 grams.
3. the gel ointment that swells and ache according to claim 1 and 2 is characterized in that the amount that ointment-containing body in every subsides gel ointment contains the medicine that swells and ache is 2.0 grams～4.0 grams.
4. the gel ointment that swells and ache according to claim 1 is characterized in that gel ointment is made up of backing layer, ointment-containing body and lid lining protecting film three parts.
5. the gel ointment that swells and ache according to claim 1 is characterized in that: by weight percentage, ointment-containing body is grouped into by following one-tenth:
Medicine 20～50% swells and ache
Basic polymer 3～10%
Cross-linking agent 0.1～1%
Organic acid 0.1～0.6%
Excipient 0～10%
Wetting agent 20～40%
Binding agent 0～10%
Purified water 15～50%.
6. the gel ointment that swells and ache according to claim 1 is characterized in that the described medicine that swells and ache is to be made by following method: take by weighing 6 parts of raw material Borneolum Syntheticums by weight ratio, 6 parts of Mentholums, Moschus add ethanol for 0.08 part makes it dissolving, 18 parts of all the other Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae)s in right amount; 18 parts of Delavay ampelopsis root, 18 parts of Folium Craibiodendri Yunnanensiss, 18 parts of Herba Veratri Taliensis, 18 parts of Radix Psammosileness, 18 parts of Radix Aconiti Brachypodi (Radix Aconiti Szechenyiani)s; 18 parts of Radix Aconiti Kusnezoffii, 18 parts of colguhoumia roots, 18 parts of Herba Erigerontiss, 18 parts of Radix Notoginseng, 18 parts of Radix et Rhizoma Dysosmatiss; 18 parts of Rhizoma Paridis, 18 parts of Fructus Gardeniae, 18 parts of Pseudobulbus Bletillae (Rhizoma Bletillae), 18 parts of the Radixs Angelicae Dahuricae, Radix Glycyrrhizae is ground into coarse powder for 6 parts; Mixing according to the percolation (an appendix I of Chinese Pharmacopoeia version in 2010 O) under fluid extract and the extractum item, is made solvent with 65～70% ethanol, carries out percolation; Collect 1000 parts of percolates, cold preservation 48 hours is filtered, and is subsequent use; Get gel-type vehicle or solid dispersion substrate is an amount of, add above-mentioned subsequent use percolate, abundant stirring and dissolving, heated volatile is removed part ethanol in water-bath, when being chilled to 40 ℃, adds alcoholic solution such as Borneolum Syntheticum, stirs, and promptly gets 750 parts of the medicines of swelling and ache.
7. the gel ointment that swells and ache according to claim 1 is characterized in that the employed pharmaceutic adjuvant of ointment-containing body is: one or more in basic polymer, cross-linking agent, organic acid, excipient, wetting agent, binding agent, the distilled water; The employed back lining materials of backing layer can be a kind of in cotton, non-woven fabrics, the flannel; Lid lining protecting film employed lid lining material can be a kind of in separate paper, polypropylene film, polyethylene film, cellophane, polyester, the aluminium foil-polyethylene composite film.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110366880.0A CN102406840B (en) | 2011-11-18 | 2011-11-18 | Gel binder for treating swelling and pain and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110366880.0A CN102406840B (en) | 2011-11-18 | 2011-11-18 | Gel binder for treating swelling and pain and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102406840A true CN102406840A (en) | 2012-04-11 |
| CN102406840B CN102406840B (en) | 2015-01-21 |
Family
ID=45909375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110366880.0A Active CN102406840B (en) | 2011-11-18 | 2011-11-18 | Gel binder for treating swelling and pain and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102406840B (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102860991A (en) * | 2012-10-10 | 2013-01-09 | 杭州华东医药集团生物工程研究所有限公司 | Medicine composition containing febuxostat and preparation method thereof |
| CN103272028A (en) * | 2013-06-22 | 2013-09-04 | 昆明赛诺制药有限公司 | Medicine for curing traumatic injuries and rheumatic pain |
| CN103341135A (en) * | 2013-05-31 | 2013-10-09 | 广州花海药业股份有限公司 | Gel agent for treating arthralgia and preparing method thereof |
| CN103830514A (en) * | 2014-03-27 | 2014-06-04 | 贵州维康药业有限公司 | Externally-used patch for treating gout and preparation method thereof |
| CN107157806A (en) * | 2017-05-27 | 2017-09-15 | 南方医科大学 | It is a kind of suitable for gel-type vehicle of 3D printing facial mask and its preparation method and application |
| CN108641104A (en) * | 2018-04-11 | 2018-10-12 | 中国人民解放军第七医院 | A kind of water base cross-linked polymer and its preparation method and application |
| CN108653245A (en) * | 2018-07-06 | 2018-10-16 | 张文涛 | A kind of hydrogel transdermal patch and preparation method thereof of the pure plant extract oil containing there are many |
| CN109820955A (en) * | 2019-04-12 | 2019-05-31 | 尤刚 | A kind of dissolving blood stasis and detoxication cream and preparation method thereof |
| CN114533805A (en) * | 2022-03-18 | 2022-05-27 | 南岛南药健康产业投资(海南)有限公司 | External prescription for cervical and lumbar diseases |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1723928A (en) * | 2005-07-07 | 2006-01-25 | 云南省药物研究所 | External use medicinal composition for treating swelling paint |
| CN101879250A (en) * | 2010-06-25 | 2010-11-10 | 安舒贴(天津)外用制剂科技有限公司 | Arthralgia relief gel paste and preparation method |
-
2011
- 2011-11-18 CN CN201110366880.0A patent/CN102406840B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1723928A (en) * | 2005-07-07 | 2006-01-25 | 云南省药物研究所 | External use medicinal composition for treating swelling paint |
| CN101879250A (en) * | 2010-06-25 | 2010-11-10 | 安舒贴(天津)外用制剂科技有限公司 | Arthralgia relief gel paste and preparation method |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102860991A (en) * | 2012-10-10 | 2013-01-09 | 杭州华东医药集团生物工程研究所有限公司 | Medicine composition containing febuxostat and preparation method thereof |
| CN103341135A (en) * | 2013-05-31 | 2013-10-09 | 广州花海药业股份有限公司 | Gel agent for treating arthralgia and preparing method thereof |
| CN103341135B (en) * | 2013-05-31 | 2015-04-22 | 广州花海药业股份有限公司 | Gel agent for treating arthralgia and preparing method thereof |
| CN103272028A (en) * | 2013-06-22 | 2013-09-04 | 昆明赛诺制药有限公司 | Medicine for curing traumatic injuries and rheumatic pain |
| CN103272028B (en) * | 2013-06-22 | 2015-10-07 | 昆明赛诺制药有限公司 | A kind of medicine for the treatment of traumatic injury and rheumatic arthralgia |
| CN103830514A (en) * | 2014-03-27 | 2014-06-04 | 贵州维康药业有限公司 | Externally-used patch for treating gout and preparation method thereof |
| CN107157806A (en) * | 2017-05-27 | 2017-09-15 | 南方医科大学 | It is a kind of suitable for gel-type vehicle of 3D printing facial mask and its preparation method and application |
| CN107157806B (en) * | 2017-05-27 | 2020-05-26 | 南方医科大学 | Gel matrix suitable for 3D printing mask and preparation method and application thereof |
| CN108641104A (en) * | 2018-04-11 | 2018-10-12 | 中国人民解放军第七医院 | A kind of water base cross-linked polymer and its preparation method and application |
| CN108653245A (en) * | 2018-07-06 | 2018-10-16 | 张文涛 | A kind of hydrogel transdermal patch and preparation method thereof of the pure plant extract oil containing there are many |
| CN108653245B (en) * | 2018-07-06 | 2021-05-11 | 张文涛 | Hydrogel transdermal patch containing various pure plant extract oils and preparation method thereof |
| CN109820955A (en) * | 2019-04-12 | 2019-05-31 | 尤刚 | A kind of dissolving blood stasis and detoxication cream and preparation method thereof |
| CN114533805A (en) * | 2022-03-18 | 2022-05-27 | 南岛南药健康产业投资(海南)有限公司 | External prescription for cervical and lumbar diseases |
| CN114533805B (en) * | 2022-03-18 | 2024-02-02 | 南岛南药健康产业投资(海南)有限公司 | External prescription for cervical vertebra and lumbar vertebra diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102406840B (en) | 2015-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102406840B (en) | Gel binder for treating swelling and pain and its preparation method | |
| CN100542585C (en) | A kind of externally-applied medicinal composition with analgesia and antiinflammatory action | |
| CN103169928B (en) | Externally applied traditional Chinese medicine composition for treating dysmenorrhea, as well as preparation method and application thereof | |
| CN101036677B (en) | Compound panax notoginseng cataplasma | |
| CN103041173A (en) | Traditional Chinese medicine external preparation for curing dermatitis and eczema and preparing method thereof | |
| CN102861116B (en) | Method for preparing pericarpium granati polyphenol gel for treating gynecological inflammation | |
| CN101732668B (en) | Preparation method of Chinese medicinal composition for treating urinary system infection | |
| CN104274546A (en) | Externally-applied traditional Chinese medicine composition, externally-applied traditional Chinese medicine preparation as well as preparation method and application of externally-applied traditional Chinese medicine composition | |
| CN106176784A (en) | A kind of pharmaceutical composition for dermatitis, application, preparation and preparation method thereof | |
| CN103735712A (en) | Preparation method of Chinese medicinal composition and Chinese medicinal composition prepared by using preparation method | |
| CN100438896C (en) | External use muscle relaxing preparation for treating traumatic injury and rheumatism stagnation pain and its preparing method | |
| CN100450517C (en) | Dysmenorrhea treating Chinese traditional medicine preparation | |
| CN105596587A (en) | Composition for relieving swelling and pain | |
| CN105287742A (en) | Ointment capable of controlling mosquito bite and preparation method thereof | |
| CN102038821B (en) | Method for preparing medicinal composition for treating dysmenorrhea | |
| CN115227679A (en) | Musk pain-relieving gel plaster and preparation method thereof | |
| CN107412661A (en) | A kind of Chinese medicine composition for treating impotence, premature ejaculation and preparation method thereof | |
| CN103933232A (en) | Anti-inflammatory antalgic oral preparation, preparing process thereof and uses thereof | |
| CN102940684A (en) | Traditional Chinese medicine composition containing illicium henryi and preparation method thereof | |
| CN100475236C (en) | Medicine composition for treating women's pulvic infection, prepn process and use thereof | |
| CN102145152B (en) | Tradition Chinese medicinal preparation for treating cyclomastopathy and preparation method thereof | |
| TWI409076B (en) | Medical herb composition for increasing inflammation, swell and pain, method for manufacturing medical herb abstract, application for the same | |
| CN101337026A (en) | External medicine composition for treating gout | |
| CN102579783A (en) | Cataplasm for curing acute injury of soft tissues and preparation method thereof | |
| CN112656896B (en) | External traditional Chinese medicine composition for treating haemorrhoids and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20120411 Assignee: Yunnan Baiyao Group Co.,Ltd. Assignor: YUNNAN INSTITUTE OF MATERIA MEDICA Contract record no.: X2022530000005 Denomination of invention: A swelling and pain gel plaster and its preparation method Granted publication date: 20150121 License type: Common License Record date: 20220624 |